EBP-921
N/A
Report date: 2022/07/04 19:38:02
NME
Base Information
Drug NameEBP-921
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesEiger Biopharmaceuticals Inc
Active IndicationsN/A
Inactive Indications
Other Information
ATC CodeN/A
Related LinksN/A